论文部分内容阅读
目的探讨阿托伐他汀对糖耐量减低的原发性高血压(EH)患者血管内皮功能的影响。方法 EH合并糖耐量减低患者96例,随机分为对照组(常规治疗,50例),阿托伐他汀组(常规治疗+阿托伐他汀20mg/d,46例)。观察治疗前和治疗8周后血脂、血糖及血压变化,采用流式细胞术检测治疗前后外周血CD31+/AnnexinV+内皮微粒(EMPs)数量。结果治疗后,阿托伐他汀组外周血EMPs数量明显减少[(2342.5±856.2)个/ml vs.(1806.7±761.7)个/ml](P<0.01),对照组无明显变化[(2251.8±832.5)个/ml vs.(2152.5±815.1)个/ml](P>0.05)。治疗后,阿托伐他汀组甘油三酯(TG)、总胆固醇(TC)及低密度脂蛋白(LDL)水平明显低于对照组(P<0.05)。结论阿托伐他汀能显著降低EH合并糖耐量减低患者外周血EMPs数量,减轻内皮凋亡和损伤。
Objective To investigate the effect of atorvastatin on vascular endothelial function in patients with impaired glucose tolerance (EH). Methods Ninety-six patients with EH combined with impaired glucose tolerance were randomly divided into control group (n = 50) and atorvastatin group (n = 20). The changes of blood lipids, blood glucose and blood pressure before and 8 weeks after treatment were observed. The numbers of CD31 + / AnnexinV + endothelial cells (EMPs) in peripheral blood before and after treatment were detected by flow cytometry. Results After treatment, the number of EMPs in atorvastatin group was significantly decreased [(2342.5 ± 856.2) / ml vs. (1806.7 ± 761.7) / ml] (P <0.01), while there was no significant change in control group [(2251.8 ± 832.5) cells / ml vs. (2152.5 ± 815.1) cells / ml] (P> 0.05). After treatment, triglyceride (TG), total cholesterol (TC) and low density lipoprotein (LDL) levels in atorvastatin group were significantly lower than those in control group (P <0.05). Conclusions Atorvastatin can significantly reduce the number of EMPs in peripheral blood and reduce the apoptosis and injury of endothelial cells in EH patients with impaired glucose tolerance.